Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 659

1.

Retraction notice to "Sun exposure related methylation in malignant and non-malignant skin lesions" [Cancer Letters 245/1-2 (2007) 112-120].

Sathyanarayana UG, Moore AY, Li L, Padar A, Majmudar K, Stastny V, Makarla P, Suzuki M, Minna JD, Feng Z, Gazdar AF.

Cancer Lett. 2018 Sep 28;432:272. doi: 10.1016/j.canlet.2018.07.010. No abstract available.

PMID:
30007586
2.

Dysregulation of fibulin-5 and matrix metalloproteases in epithelial ovarian cancer.

Manders DB, Kishore HA, Gazdar AF, Keller PW, Tsunezumi J, Yanagisawa H, Lea J, Word RA.

Oncotarget. 2018 Feb 14;9(18):14251-14267. doi: 10.18632/oncotarget.24484. eCollection 2018 Mar 6.

3.

Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, Oliver TG, Minna JD, Gazdar AF.

Transl Lung Cancer Res. 2018 Feb;7(1):32-49. doi: 10.21037/tlcr.2018.02.02.

4.

Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?

Gazdar AF.

J Thorac Oncol. 2018 Feb;13(2):148-150. doi: 10.1016/j.jtho.2017.11.004. No abstract available.

PMID:
29425612
5.

The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.

He M, Liu S, Gallolu Kankanamalage S, Borromeo MD, Girard L, Gazdar AF, Minna JD, Johnson JE, Cobb MH.

Transl Oncol. 2018 Apr;11(2):292-299. doi: 10.1016/j.tranon.2018.01.004. Epub 2018 Feb 2.

6.

Small-cell lung cancer: what we know, what we need to know and the path forward.

Gazdar AF, Bunn PA, Minna JD.

Nat Rev Cancer. 2017 Nov 10;17(12):765. doi: 10.1038/nrc.2017.106. [Epub ahead of print]

PMID:
29123245
7.

Small-cell lung cancer: what we know, what we need to know and the path forward.

Gazdar AF, Bunn PA, Minna JD.

Nat Rev Cancer. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. Review. Erratum in: Nat Rev Cancer. 2017 Nov 10;:.

PMID:
29077690
8.

GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.

Kasiri S, Shao C, Chen B, Wilson AN, Yenerall P, Timmons BC, Girard L, Tian H, Behrens C, Wistuba II, Gazdar AF, Kim J.

Cancer Res. 2017 Aug 15;77(16):4448-4459. doi: 10.1158/0008-5472.CAN-16-3315. Epub 2017 Jun 26.

PMID:
28652248
9.

Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, Behrens C, Mino B, Villalobos P, Parra ER, Suraokar M, Pataer A, Swisher SG, Kalhor N, Bhanu NV, Garcia BA, Heymach JV, Coombes K, Xie Y, Girard L, Gazdar AF, Kittler R, Wistuba II, Minna JD, Martinez ED.

Cell Rep. 2017 May 23;19(8):1669-1684. doi: 10.1016/j.celrep.2017.04.077.

10.

Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.

Qiu ZW, Bi JH, Gazdar AF, Song K.

Genes Chromosomes Cancer. 2017 Jul;56(7):559-569. doi: 10.1002/gcc.22460. Epub 2017 May 4.

11.

Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently over-expressed and functions as an oncogene in several tumor types.

Windhorst S, Song K, Gazdar AF.

Biochem Pharmacol. 2017 Aug 1;137:1-9. doi: 10.1016/j.bcp.2017.03.023. Epub 2017 Apr 2. Review.

12.

Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Çeliktas M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, Wang H, Behrens C, Do KA, Gazdar AF, Hanash SM, Taguchi A.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-9. doi: 10.1093/jnci/djw231.

13.

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H.

Cancer Cell. 2017 Feb 13;31(2):225-239. doi: 10.1016/j.ccell.2017.01.005.

14.

Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.

Pelosof L, Ahn C, Gao A, Horn L, Madrigales A, Cox J, McGavic D, Minna JD, Gazdar AF, Schiller J.

J Natl Cancer Inst. 2017 Jan 28;109(7). doi: 10.1093/jnci/djw295. Print 2017 Jan.

PMID:
28132018
15.

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.

Tagal V, Wei S, Zhang W, Brekken RA, Posner BA, Peyton M, Girard L, Hwang T, Wheeler DA, Minna JD, White MA, Gazdar AF, Roth MG.

Nat Commun. 2017 Jan 19;8:14098. doi: 10.1038/ncomms14098.

16.

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, Berrett KC, Mosbruger TL, Wang J, Kohan JL, Salama ME, Witt BL, Peifer M, Thomas RK, Gertz J, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML, Oliver TG.

Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005. Epub 2017 Jan 12.

17.

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.

Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF.

EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28.

18.

ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.

Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, Girard L, Behrens C, Wistuba II, Gazdar AF, Hayward NK, Minna JD.

J Clin Invest. 2016 Sep 1;126(9):3219-35. doi: 10.1172/JCI76725. Epub 2016 Aug 8.

19.

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.

Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, Girard L, Minna JD, Gazdar AF, Cobb MH, Johnson JE.

Cell Rep. 2016 Aug 2;16(5):1259-1272. doi: 10.1016/j.celrep.2016.06.081. Epub 2016 Jul 21.

20.

An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.

Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD, Wistuba II, Minna JD, Gazdar AF.

Clin Cancer Res. 2016 Oct 1;22(19):4880-4889. Epub 2016 Jun 28.

21.

Correction: "From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers".

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2016 Jul;11(7):e88-9. doi: 10.1016/j.jtho.2016.04.003. No abstract available.

22.

Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.

Kim DW, Wu N, Kim YC, Cheng PF, Basom R, Kim D, Dunn CT, Lee AY, Kim K, Lee CS, Singh A, Gazdar AF, Harris CR, Eisenman RN, Park KS, MacPherson D.

Genes Dev. 2016 Jun 1;30(11):1289-99. doi: 10.1101/gad.279307.116.

23.

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, Reynolds CP, Lam WL, Lea J, Gazdar AF.

Oncotarget. 2016 Jun 10;8(31):50489-50499. doi: 10.18632/oncotarget.9929. eCollection 2017 Aug 1.

24.

Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer.

Gazdar AF, Minna JD.

J Natl Cancer Inst. 2016 May 31;108(10). pii: djw119. doi: 10.1093/jnci/djw119. Print 2016 Oct. No abstract available.

PMID:
27247352
25.

ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers.

Wang YW, Ma X, Zhang YA, Wang MJ, Yatabe Y, Lam S, Girard L, Chen JY, Gazdar AF.

J Thorac Oncol. 2016 Sep;11(9):1469-81. doi: 10.1016/j.jtho.2016.05.010. Epub 2016 May 24.

26.

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.

Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW, Minna JD.

Oncotarget. 2016 May 31;7(22):31639-51. doi: 10.18632/oncotarget.9335.

27.

Inhibiting the Jumonji family: a potential new clinical approach to targeting aberrant epigenetic mechanisms.

Martinez ED, Gazdar AF.

Epigenomics. 2016 Mar;8(3):313-6. doi: 10.2217/epi.15.115. Epub 2016 Feb 26. No abstract available.

PMID:
26918824
28.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

29.

Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.

Zhang YA, Ma X, Sathe A, Fujimoto J, Wistuba I, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, Larsen JE, Girard L, Liu X, Song K, Behrens C, Kalhor N, Xie Y, Zhang MQ, Minna JD, Gazdar AF.

J Thorac Oncol. 2016 Mar;11(3):346-360. doi: 10.1016/j.jtho.2015.11.004. Epub 2015 Dec 25.

30.

From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2016 Mar;11(3):287-99. doi: 10.1016/j.jtho.2015.10.009. Epub 2015 Dec 24. Review. Erratum in: J Thorac Oncol. 2016 Jul;11(7):e88-9.

31.

Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma.

Soh J, Toyooka S, Matsuo K, Yamamoto H, Wistuba II, Lam S, Fong KM, Gazdar AF, Miyoshi S.

Oncol Lett. 2015 Sep;10(3):1775-1782. Epub 2015 Jun 23.

32.

Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.

Hubaux R, Thu KL, Vucic EA, Pikor LA, Kung SH, Martinez VD, Mosslemi M, Becker-Santos DD, Gazdar AF, Lam S, Lam WL.

Int J Cancer. 2015 Nov 1;137(9):2072-82. doi: 10.1002/ijc.29577. Epub 2015 May 6.

33.

Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.

Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, Zhang Q, Chin A, Wong CH, Wang H, McFerrin L, Selamat SA, Yang C, Kroh EM, Garg KS, Behrens C, Gazdar AF, Laird-Offringa IA, Tewari M, Wistuba II, Thiery JP, Hanash SM.

Cancer Res. 2015 May 1;75(9):1789-800. doi: 10.1158/0008-5472.CAN-14-2535. Epub 2015 Mar 5.

34.

The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.

Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, MacPherson D, McFadden DG, Farago A, Jacks T, Travis WD, Brambilla E.

J Thorac Oncol. 2015 Apr;10(4):553-64. doi: 10.1097/JTO.0000000000000459.

35.

Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling.

Borkowski R, Du L, Zhao Z, McMillan E, Kosti A, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, White MA, Pertsemlidis A.

Cancer Res. 2015 Feb 15;75(4):666-75. doi: 10.1158/0008-5472.CAN-14-1329. Epub 2014 Dec 17.

36.

Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Taguchi A, Delgado O, Celiktaş M, Katayama H, Wang H, Gazdar AF, Hanash SM.

Proteomics. 2014 Dec;14(23-24):2750-9. doi: 10.1002/pmic.201400378. Epub 2014 Nov 20.

37.

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.

Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93. doi: 10.1073/pnas.1410419111. Epub 2014 Sep 29.

38.

A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets.

Taguchi A, Taylor AD, Rodriguez J, Celiktaş M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM.

Cancer Res. 2014 Sep 1;74(17):4694-705. doi: 10.1158/0008-5472.CAN-13-3725. Epub 2014 Jun 26.

39.

Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T.

Hum Mutat. 2014 Jun;35(6):756-65. doi: 10.1002/humu.22556. Epub 2014 May 6. Review.

40.

Methylation analysis in spontaneous sputum for lung cancer diagnosis.

Hubers AJ, van der Drift MA, Prinsen CF, Witte BI, Wang Y, Shivapurkar N, Stastny V, Bolijn AS, Hol BE, Feng Z, Dekhuijzen PN, Gazdar AF, Thunnissen E.

Lung Cancer. 2014 May;84(2):127-33. doi: 10.1016/j.lungcan.2014.01.019. Epub 2014 Jan 31.

PMID:
24598366
41.

Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer.

Delgado O, Batten KG, Richardson JA, Xie XJ, Gazdar AF, Kaisani AA, Girard L, Behrens C, Suraokar M, Fasciani G, Wright WE, Story MD, Wistuba II, Minna JD, Shay JW.

Clin Cancer Res. 2014 Mar 15;20(6):1610-22. doi: 10.1158/1078-0432.CCR-13-2589. Epub 2014 Jan 31.

42.

EGFR mutations in lung cancer: different frequencies for different folks.

Gazdar AF.

J Thorac Oncol. 2014 Feb;9(2):139-40. doi: 10.1097/JTO.0000000000000063. No abstract available.

43.

Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.

Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA.

Cell. 2013 Oct 24;155(3):552-66. doi: 10.1016/j.cell.2013.09.041. Epub 2013 Oct 24.

44.

YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway.

Pikor LA, Lockwood WW, Thu KL, Vucic EA, Chari R, Gazdar AF, Lam S, Lam WL.

Cancer Res. 2013 Dec 15;73(24):7301-12. doi: 10.1158/0008-5472.CAN-13-1897. Epub 2013 Oct 29.

45.

The pivotal role of pathology in the management of lung cancer.

Davidson MR, Gazdar AF, Clarke BE.

J Thorac Dis. 2013 Oct;5 Suppl 5:S463-78. doi: 10.3978/j.issn.2072-1439.2013.08.43. Review.

46.

EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.

Wilson IM, Vucic EA, Enfield KS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TP, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, Lam WL.

Oncogene. 2014 Sep 4;33(36):4464-73. doi: 10.1038/onc.2013.396. Epub 2013 Oct 7.

47.

Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.

Coe BP, Thu KL, Aviel-Ronen S, Vucic EA, Gazdar AF, Lam S, Tsao MS, Lam WL.

PLoS One. 2013 Aug 15;8(8):e71670. doi: 10.1371/journal.pone.0071670. eCollection 2013.

48.

Precision medicine for cancer patients: lessons learned and the path forward.

Gazdar AF, Minna JD.

J Natl Cancer Inst. 2013 Sep 4;105(17):1262-3. doi: 10.1093/jnci/djt219. Epub 2013 Aug 20. No abstract available.

49.

Progenitor cell line (hPheo1) derived from a human pheochromocytoma tumor.

Ghayee HK, Bhagwandin VJ, Stastny V, Click A, Ding LH, Mizrachi D, Zou YS, Chari R, Lam WL, Bachoo RM, Smith AL, Story MD, Sidhu S, Robinson BG, Nwariaku FE, Gazdar AF, Auchus RJ, Shay JW.

PLoS One. 2013 Jun 13;8(6):e65624. doi: 10.1371/journal.pone.0065624. Print 2013.

50.

DNA methylation data analysis and its application to cancer research.

Ma X, Wang YW, Zhang MQ, Gazdar AF.

Epigenomics. 2013 Jun;5(3):301-16. doi: 10.2217/epi.13.26. Review.

Supplemental Content

Loading ...
Support Center